๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Safety and efficacy of carotid stenting in the very elderly

โœ Scribed by Arthur Grant; Christopher White; Gary Ansel; Michael Bacharach; Christopher Metzger; Carlos Velez


Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
159 KB
Volume
75
Category
Article
ISSN
1522-1946

No coin nor oath required. For personal study only.

โœฆ Synopsis


Abstract

Background: Carotid artery stenting (CAS) has emerged as an alternative to carotid endarterectomy (CEA) in patients at high risk for complications from surgery. The very elderly (โ‰ฅ80โ€yearโ€old) are one subgroup of patients identified as being at increased risk for carotid surgery. However, there is concern that the very elderly are also at increased risk for complications of CAS. A stroke and death rate of 12% was reported in very elderly patients during the rollโ€in phase of Carotid Revascularization Endarterectomy versus Stent Trial (CREST). We are reporting on a large clinical series of CAS with independent neurological assessment in the very elderly. Methods: Between 1994 and 2008, a consecutive series of 418 CAS patients (โ‰ฅ80โ€yearโ€old) were treated at four highโ€volume centers with extensive CAS experience. Independent neurologic assessment was performed after CAS procedures. Thirtyโ€day followโ€up information was available in 389 patients. Results: The average age was 83.2 ยฑ 2.8 years. Most patients were male (63.2%), and the target lesion carotid stenosis was asymptomatic in twoโ€thirds (68.2%) of patients. The majority of patients treated with CAS had a history of coronary artery disease (74.4%), hypertension (87.8%), and dyslipidemia (71.1%). One third (30.1%) were diabetic and more than half (56.5%) were current or former smokers. Embolic protection devices (EPD) were used in 78.7% of cases with the CAS procedure being performed before EPD availability being the most common reason for not using them. The overall 30โ€day incidence of stroke and death was 2.8% (11/389). The cumulative incidence of major cardiovascular events (stroke, death, or myocardial infarction) during that time period was 3.3% (13/389). Conclusions: This large series of CAS with independent neurologic assessment is convincing evidence that the very elderly (โ‰ฅ80 years) can safely undergo CAS with stroke and death rates comparable to younger patients. The key to obtaining these excellent results is that CAS be performed by high volume, experienced operators who exercise restraint regarding patient selection. ยฉ 2009 Wileyโ€Liss, Inc.


๐Ÿ“œ SIMILAR VOLUMES


The Safety Profile of Fluvoxamine in Eld
โœ WOLFGANG WAGNER; VINCENT HOUSER; LUNG FAI WONG ๐Ÿ“‚ Article ๐Ÿ“… 1996 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 493 KB ๐Ÿ‘ 1 views

The safety profile of fluvoxamine was assessed in 4843 elderly, mainly depressed patients (65 years or older; range 65 to 97 years) enrolled in worldwide post-marketing studies. This cohort of elderly patients was extracted from a population of 34 587 patients in whom the safety profile of fluvoxami